Vazyme Is A Trusted Upstream Partner with Large-scale Capabilities in The Biosynthesis of Semaglutide Intermediates

• Direct contact technical support
• Find products for your research

Fuel your semaglutide therapies with Vazyme’s P29 peptide intermediate—the reliable, scalable, and high-quality building block behind Ozempic® and Wegovy®. Our cutting-edge fermentation and proprietary enzyme technology deliver over 30 kg of purified P29 per 5,000L batch, maximizing yield and efficiency.

With an annual capacity exceeding 2,000 kg and over 100 kg in safety stock, Vazyme guarantees uninterrupted, large-scale supply for global pharmaceutical partners. We are committed to regulatory excellence, actively pursuing FDA DMF and international approvals to ensure full compliance.

Partner with Vazyme to accelerate your semaglutide production, reduce costs, and secure a trusted source of critical peptide intermediates. Innovation, scalability, and reliability—Vazyme delivers them all.

Vazyme P29 Peptide Intermediate: Secure, Scalable, and Reliable Supply for Semaglutide Manufacturing

The demand for semaglutide-based therapies, such as Ozempic® and Wegovy®, continues to grow rapidly worldwide. At the heart of these innovative medicines lies the P29 peptide intermediate, a critical building block for active pharmaceutical ingredient (API) production.

Vazyme stands at the forefront of peptide biotechnology, delivering the most advanced P29 peptide intermediate solution available on the market. With world-class fermentation technology and proprietary enzyme platforms, Vazyme ensures both quality and scalability to meet the evolving needs of global pharmaceutical partners.

Efficient Fermentation: Each 5,000L batch yields more than 30 kg of purified P29 peptide intermediate, powered by our high-efficiency, in-house enzyme technology. This biocatalysis-driven approach not only maximizes yield but also reduces costs compared to traditional chemical synthesis.

Large-Scale Production: With an annual production capacity exceeding 2,000 kg, Vazyme operates the largest P29 manufacturing facility in China. This enables long-term supply security for pharmaceutical companies scaling up semaglutide production.

Reliable Supply: Vazyme maintains more than 100 kg of safety stock, ensuring uninterrupted delivery and supply chain stability. Our partners benefit from minimized risks and guaranteed access to critical raw materials.

Regulatory Commitment: To support our global partners, Vazyme is actively pursuing FDA DMF submissions and further regulatory registrations, ensuring full compliance with international pharmaceutical standards.

By choosing Vazyme’s P29 peptide intermediate, semaglutide manufacturers gain a partner that combines biotechnological innovation, large-scale capacity, and reliable global supply.

With a proven track record of excellence and a dedication to advancing next-generation therapeutic production, Vazyme is the trusted partner for pharmaceutical companies seeking efficiency, scalability, and security in peptide manufacturing.

Contact your account manager to learn more about Vazyme’s peptide solutions and how we can accelerate your semaglutide production pipeline.